• LMICs are often deprioritised launch markets for innovative breakthrough therapies – but is the #WHO prequalificati… https://t.co/t9QrkHgL2U
  • PELLEPHARM granted #BreakthroughDesignation and #OrphanDrug Designation from #FDA for patidegib as topical treatmen… https://t.co/WikemxbZBj
  • $JNJ JANSSEN granted expanded marketing authorisation by #EU_Commission for ZYTIGA as treatment for patients with e… https://t.co/rePs7Lb8Cp
  • #CBPartners congratulates Carlos Vazquez on his promotion to Senior Analyst! Carlos is a seasoned author of thought… https://t.co/GZk6ww9OUL
  • #CBPartners congratulates Bami Oshinowo on her promotion to Principal as she becomes a member of the Leadership Tea… https://t.co/qi0x1w1okc
Prev Next

CBPartners Releases Revolutionary New Pricing App

03 October 2014 CBPartners, a global leader in consulting services to the life sciences industry, has released a ground-breaking new app. The eponymous CBPartners app, available through iTunes, offers users free centralised, mobile access to current international reference pricing rules in a convenient, visual user interface.

“As International Reference Pricing (IRP) presents increasingly complex challenges to today's healthcare stakeholders, the CBPartners iPhone app provides a user-friendly platform for accessing IRP rules when you need them most,” says Theodore D. Schroeder, a CBPartners Pricing & Market Access specialist.

With years of experience providing strategic support to pharmaceutical companies, biopharmaceutical companies, medical device companies, and government health authorities, CBPartners is proud to present the CBPartners iPhone app. “International Reference Pricing rules are often treated as a trade secret,” says CBPartners’ Chief Executive Officer and CEO Cyrus Chowdhury. “Our app proves that it is how these rules are applied, not the data itself, that is the key to successful global pricing strategy. That’s why we decided to go with a free model, and release this data to clients, competitors, and the general public. Our value is in the strategic guidance we provide to our clients – not data.”

In addition to showcasing in-depth IRP rules for key markets spanning the EU, LatAm, Asia-Pac, Middle East, and other emerging markets, the CBPartners app details reference countries, referenced countries, referencing frequency, referencing formality, and referencing mechanisms. Live updates are added as new policies are defined and existing policies evolve. The app is available for download on Apple devices through iTunes, at http://bit.ly/CBPartnersApp .

“It’s difficult to argue that anyone’s IRP rule set is the correct one. Rules are unique to each product, and do evolve with time. The main advantage of our IRP rules delivered through the app is that they are updated on an ongoing basis. The user downloads the app once, and is forever updated on rule changes as our team of experts discover them through our engagement work,” states Monica Martin de Bustamante, Managing Director at CBPartners.

The app also features an “Ask CBPartners” function, which connects users directly with the firm’s pricing experts to further understand IRP rules and implications. In-app content includes CBPartners’ thought leadership, such as CBPartners’ latest white papers, blog posts, press releases, and live Twitter feed, which are all updated in real-time.

CBPartners continues to lead the industry in thought leadership on pharmaceutical and biopharmaceutical issues through its five practices. To learn more about the firm’s perspectives and capabilities, please visit http://www.cbpartners.com.

About CBPartners
CBPartners is a leading global strategy consulting firm focusing on healthcare issues for a variety of clients, including biopharmaceutical companies, medical device companies and government health authorities. Headquartered in New York City, CBPartners maintains a continuous throughput of local market intelligence updates from advisors throughout over 75 markets. CBPartners provides expertise through five practice areas including Pricing and Market Access, Value Demonstration, Portfolio Optimisation, Commercial Planning, and Government Policy Advisory.

CBPartners Announces New Website

New York City, July 10, 2014 – CBPartners, a global leader in consulting services to the life sciences industry, has launched a new website. The redesigned site boasts improved navigation and mobile responsiveness, as well as increased access to the firm’s thought pieces, blog posts, and conference presentations.

“The new cbpartners.com provides an ideal platform to showcase our insights, capabilities, and to provide timely updates on global health access issues,” says CBPartners’ Chief Executive Officer, Cyrus Chowdhury. “An enhanced online presence is essential in our commitment to provide unparalleled service to our clients. Our insights around how the industry is evolving, how policy is changing, and how strategic commercial imperatives must be evaluated are now more accessible than ever.”

As the market landscape evolves, clients and consultants alike rely increasingly on real-time updates via news feeds and Twitter. “Our revamped website integrates social media platforms to keep clients informed,” explains Sam Foner, CBPartners’ head of Marketing and Operations.

Through the new site’s ‘Ask Us Anything’ function, new clients can raise questions through the website, and receive insights within 24 hours. Managing Director Monica Martin de Bustamante further explains, “As part of a greater push to extend our responsiveness beyond that of any other life sciences consultancy in the world, we are working on launching several exciting developments in the coming months, including mobile applications leveraging the connectivity of our new website.”

CBPartners continues to lead the industry in thought leadership on pharmaceutical and biopharmaceutical issues through its five practices. To learn more about the firm’s perspectives and capabilities, please visit http://www.cbpartners.com.

About CBPartners CBPartners is a leading global strategy consulting firm focusing on healthcare issues for a variety of clients, including biopharmaceutical companies, medical device companies and government health authorities. Headquartered in New York City, CBPartners maintains a continuous throughput of local market intelligence updates from advisors throughout 73 markets. CBPartners provides expertise through five practice areas including Pricing and Market Access, Value Demonstration, Portfolio Optimisation, Commercial Planning, and Government Policy Advisory.

CBPartners Announces the Release of the 2013 Year-in-Review with Outlook for 2014

The report includes perspectives from CBPartners’ senior leadership team and the firm’s Global Health Advisory Board

New York City, January 30, 2014 – CBPartners, a global leader in pricing, market access, health economics / value demonstration, and commercial planning, released its annual Year-in-Review report for 2013.  The report also includes prospective viewpoints on how each major trend from the past year will likely evolve during the next year.

The report spans a variety of issues involving both established and emerging markets.  Some of the topics covered include:
  • America’s Boiling Point: Physician / Payer Pricing Reactions
  • The ACA and Its Discontents
  • AMNOG at Three Years: First ‘Major Benefit’ Scores, Comparator Selection, and Retrospective Reviews
  • UK Looks in the Mirror
  • The Future of NICE / PPRS / VBP
  • CHN’s Corruption
  • CHN Access Landscape: Some Things Don’t Change
  • Emerging HTA: CEESP in FRA, PCORI in the USA, IETS in COL, IPTs in ESP, NICE International, STD in TUR, and Pan-European HTA
  • Evolving Access Landscape: CHN Self-pay Dominates, Oral Oncolytics in BRA, Private Health Insurance, Alternative Access in ITA, and FDA’s ‘Breakthrough Status’
  • Biosimilars: Access and Substitution Policy, Regulatory Issues, and Landmark Approvals and Originator Responses
  • IP: The Sun in IND Continues to Set on Patent Law and ANVISA’s Potential New Role in Patent Recognition
  • International Collaboration
  • Modelling Revolution / Evolution
  • Summary

“2014 will be a year where many long-awaited policies will be announced and implemented, ranging from nascent HTA processes to biosimilar substitutability,” explains Mr. Cyrus A. Chowdhury, Chief Executive Officer of CBPartners.  “Understanding the past year’s events in a comprehensive manner should help our clients to better plan for the year ahead.”

The report was authored by Mr. Chowdhury, as well as Mrs. Monica Martin de Bustamante, Dr. Rachel Beckerman, Dr. Kevin Wong, Dr. Sandeep Duttagupta, and Mr. Andrew J. Gould.

CBPartners continues to lead the world in thought leadership on pharmaceutical and biopharmaceutical issues through its five practices led by consultants with extensive launch experience in both established and emerging markets.

For more information on receiving a free copy of the 2013 Year-in-Review, please email cyrus.chowdhury@cbpartners.com.

About CBPartners
CBPartners is a leading global strategy consulting firm focusing on healthcare issues for a variety of clients, including biopharmaceutical companies, medical device companies and government health authorities. Headquartered in New York City, CBPartners maintains a continuous throughput of local market intelligence updates from advisors throughout 73 markets. CBPartners provides expertise through five practice areas including Pricing and Market Access, Value Demonstration, Portfolio Optimisation, Commercial Planning, and Government Policy Advisory.

CBPartners Names Sandeep Duttagupta, Ph.D. Principal of Emerging Markets

Sandeep Duttagupta brings two decades of emerging markets experience gained while working in pricing, market access, and value demonstration functions at Pfizer

New York City, October 11, 2013 – CBPartners, one of the world’s leading authorities on strategic issues related to healthcare, is excited to welcome Sandeep Duttagupta, Ph.D., to lead the emerging markets business across all five practices.

With a rich history of successful launches with Pfizer in the emerging markets, Dr. Duttagupta provides clients with a strong set of real-world experiences and thought leadership to maximise the value of pharmaceutical products around the world. Prior to joining CBPartners, Dr. Duttagupta spent two decades with Pfizer, where he most recently ran the pricing and market access functions within the emerging markets. In this role, he led the development of the company’s strategic emerging markets pricing framework, devised multiple innovative access initiatives involving local banks and NGOs, developed multiple second-brand strategies to minimise international reference pricing risk and maintain market share, and implemented partnerships with Ministries of Health around the world.

CBPartners Collaborates with Merck Sharp & Dohme for Symposium on HTA and International Reference Pricing at ISPOR Latin America

The symposium will explore how Health Technology Assessment (HTA) and International Reference Pricing (IRP) are used in the region to evaluate and reward innovation within Latin America.

New York City, New York  June 30, 2013 – CBPartners, a global leader in pricing, market access, and health economics / value demonstration, will participate in a symposium developed in association with Merck Sharp & Dohme (MSD), which will evaluate the use of HTA and international reference pricing within the Latin American region. The symposium will take place during the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Fourth Latin America Conference taking place from September 12 – 14, 2013 in Buenos Aires, Argentina.

The symposium will have a particular focus on how HTA and IRP are used independently or in tandem. Key issues to be covered will include the exploration how these policy interventions can work more effectively together, and at times to the detriment of access to innovative pharmaceutical and biopharmaceutical therapies. The topic is of particular importance to governments in the region which are beginning to pilot and sometimes fully launch new policies and processes to evaluate clinical and cost-effectiveness value through the use of HTA.

The symposium will be led by moderator, Fernando Lopezmalo, Executive Director of Market Access in Latin America at MSD. Ms. Monica Martin de Bustamante, Managing Director at CBPartners, will provide perspective on the speaker panel, along with Rafael Alfonso, Scientific Director from RANDOM Foundation in Colombia.

“Every other year that ISPOR Latin America takes place, we find ourselves revisiting how HTA and IRP are incorporated within the region’s major countries’ pharmaceutical policy legislation,” states Ms. Martin de Bustamante. “As governments employ these policies, sometimes without sufficient planning, access to innovative therapies being brought to market can be inhibited. It is crucial that governments and the pharmaceutical industry work together to develop sound policy that appropriately values innovation. This symposium is one very important setting for this conversation between the parties to continue.”

For more information about the symposium, please visit http://www.cbpartners.com.

About CBPartners
CBPartners is a leading global strategy consulting firm focusing on healthcare issues for a variety of clients, including biopharmaceutical / pharmaceutical companies, medical device companies and government health authorities. Headquartered in New York City, CBPartners maintains a continuous throughput of local market intelligence updates from advisors throughout over 70 countries. CBPartners provides expertise through five practice areas including Pricing and Market Access, Value Demonstration, Portfolio Optimisation, Commercial Planning, and Government Policy Advisory.

CBPartners Leads Session on AMNOG during Full-Day Symposium on Value-Based Pricing in Istanbul, Turkey

The session took place in May 2013, and focused on elucidating Germany’s new early benefit assessment system created through AMNOG, and discussing its application to the Turkish environment

New York City, June 25, 2013 – CBPartners, a global leader in pricing, market access, and health economics / value demonstration, led a working session with the Turkish Ministry of Health in late May, which focused on discussing how pharmacoeconomics and value-based-pricing can be incorporated within Turkey’s healthcare system.

The symposium, entitled Value-Based Pricing in Health Care: Equal Impact, Equal Reimbursement? took place in Istanbul, Turkey on May 10, 2013.  Organised by the Health Economics & Policy Association in Turkey, the day included several thought leaders on HTA in Turkey, including  Dr. Hakkı Gürsöz, Deputy Director at the Turkish Medicines and Medical Devices Agency, and Dr. Ufuk Akdıkan, General Directorate of the Social Security Institution for General Health Insurance.  The session on the application of Germany’s AMNOG system was led by Mr. Cyrus A. Chowdhury, Chief Executive Officer of CBPartners.

“Turkish officials have requested pharmacoeconomic data as a part of new product reimbursement dossiers since 2009, but a formal system for evaluating the clinical or cost benefit of a new therapy has yet to take shape,” explains Mr. Chowdhury.  “Turkey has long been among the more progressive emerging markets, and the world is waiting to see how Turkey’s actions on this topic will ensue, and whether they can be applied to other emerging markets.”

Mr. Chowdhury continues, “Germany’s early-benefit assessment system developed through the AMNOG legislation is quickly becoming a high profile blueprint for many other governments evaluating how to incorporate HTA within their health care systems.  We would be quick to caution, however, that the German system is not without controversy and also takes advantage of the local environment, which includes a strong pharmacoeconomic resource pool within local acadaemia, and a robust domestic pharmaceutical industry lobby.  In other words, Germany has been able to successfully implement its new system through the support of its environment, not just its legislation.”

CBPartners continues to lead the world in thought leadership on value-based pricing and HTA through its Government Policy Advisory practice that works with both governments and government affairs executives within pharmaceutical and biopharmaceutical companies.

For more information about the session or conference, please visit www.cbpartners.com

About CBPartners
CBPartners is a leading global strategy consulting firm focusing on healthcare issues for a variety of clients, including biopharmaceutical / pharmaceutical companies, medical device companies and government health authorities. Headquartered in New York City, CBPartners maintains a continuous throughput of local market intelligence updates from advisors throughout over 70 countries. CBPartners provides expertise through five practice areas including Pricing and Market Access, Value Demonstration, Portfolio Optimisation, Commercial Planning, and Government Policy Advisory.

CBPartners Publishes Emerging Markets HTA Review Findings in Journal of Pharmaceutical Health Services Research

The findings represent some of the latest case-based analyses of HTA assessments conducted on innovative, specialty biopharmaceutical brands in major emerging economies, including Brazil, South Korea, and Taiwan.

New York City, May 31, 2013 – CBPartners, a global leader in pricing, market access, and health economics / value demonstration in the emerging markets, officially published the findings of a landmark assessment of HTA in the emerging markets. The study was published in the June 2013 issue of the Journal of Pharmaceutical Health Services Research, and uses a case-based approach to systematically assess the process and outcomes of several recent specialty therapeutic product HTA evaluations in Brazil, Korea, and Taiwan.

The study was led by Dr. Rachel Beckerman, Principal of Value Demonstration at CBPartners, who conceptualised the research and analysis with Mr. Cyrus A. Chowdhury, Chief Executive Officer of CBPartners. The research and analysis was conducted with Mr. Shinkyu Park, an Analyst at CBPartners, who has particular expertise on Asia-Pac Pricing and Market Access issues.

“Over the past few years, access and pricing in these emerging markets has become increasingly difficult for manufacturers with innovative, specialty products,” explains Dr. Beckerman. “No single policy intervention has had a more substantial impact on the access and pricing opportunity for new therapeutics than the HTA bodies in these markets. We note that the challenges are not all the same and similar approaches across these emerging markets will not suffice. Each market requires acute responsiveness to the local authorities’ demands.”

“For example, Korea’s HIRA requires many similar evidence and methodological requirements as those needed by England’s NICE,” adds Mr. Park. “However, they go a step further with a more restrictive cost-per-QALY threshold than that seen in England, and additionally throw in international reference pricing to help reduce the total budget impact.”

“We believe that this is just the beginning of more rigid HTA requirements in these emerging economies,” concludes Mr. Chowdhury. “The authorities in these markets will gradually adapt how they wield the power of HTA to a more normative mode. However, the twist is just around the corner as other emerging markets, including China, begin to develop their own HTA systems with unique mandates.”

The complete article can be purchased on the Journal’s website, and a similar piece can be found at www.cbpartners.com.

About CBPartners
CBPartners is a leading global strategy consulting firm focusing on healthcare issues for a variety of clients, including biopharmaceutical / pharmaceutical companies, medical device companies and government health authorities. Headquartered in New York City, CBPartners maintains a continuous throughput of local market intelligence updates from advisors throughout over 70 countries. CBPartners provides expertise through five practice areas including Pricing and Market Access, Value Demonstration, Portfolio Optimisation, Commercial Planning, and Government Policy Advisory.

CBPartners Runs ISPOR Workshop Evaluating Orphan and Ultra-Orphan HTA Processes Determining New Product Pricing and Market Access

The workshop evaluated orphan disease new drug pricing and market access policies across Europe, Latin America, and Asia.

New York City, May 21, 2013 – CBPartners, a global leader in orphan and ultra-orphan disease drug pricing, market access, and health economics / value demonstration, led a workshop assessing the advantages and disadvantages of different countries’ evaluation processes. The workshop used a case-based approach focusing on rare diseases including Hodgkin’s Lymphoma, Myelofibrosis, Cystic Fibrosis, Chronic Lymphocytic Leukaemia, and Madoteaux-Lamy Syndrome.

The session was led by Ms. Monica Martin de Bustamants, Managing Director at CBPartners, and Dr. Rachel Beckerman, Principal of Value Demonstration at CBPartners. Ms. Meghan Gallagher, Director of Evidence Value Development at Sanofi contributed specific perspectives on the challenges involved with modeling cost-effectiveness of therapies for rare disease, particularly when limited by countries’ existing new drug review policies.

“Orphan disease drugs are critical to patient care, but due to the disease’s dynamics, carry many limitations for evidence and modeling ability,” states Ms. Bustamante. “Although there is some recognition by policy-makers in established markets, many still do not apply a different lens for the review of these unique drugs.”

“When no adjustments in the pricing and reimbursement process are made for orphan disease drugs, the reviews rarely result in positive reimbursement decisions,” adds Dr. Beckerman. “Traditional cost per QALY methods are unlikely to properly demonstrate the value of orphan disease drugs.”

Principals from CBPartners continue to speak around the world about orphan disease drug policy development; the next public session will be at VisionGain’s 11th Pricing and Reimbursement Conference in London on July 17, 2013.

A copy of the ISPOR workshop presentation may be downloaded from the CBPartners website at www.cbpartners.com.

About CBPartners
CBPartners is a leading global strategy consulting firm focusing on healthcare issues for a variety of clients, including biopharmaceutical / pharmaceutical companies, medical device companies and government health authorities. Headquartered in New York City, CBPartners maintains a continuous throughput of local market intelligence updates from advisors throughout over 70 countries. CBPartners provides expertise through five practice areas including Pricing and Market Access, Value Demonstration, Portfolio Optimisation, Commercial Planning, and Government Policy Advisory.

CBPartners Invited to Lead Workshop on Orphan Disease Drug Access and Pricing at 2013 ISPOR International Meeting

Leading a panel of speakers from the biopharmaceutical industry and academia, CBPartners will present the challenges involved with applying traditional pricing and reimbursement policies to new therapies with orphan disease designations, as well as potential strategic solutions which may be applied in the global markets

New York City, March 15, 2013 – CBPartners, one of the world’s leading authorities on the development of pricing and market access strategy for orphan disease designated products, was officially selected by ISPOR (International Society for Pharmacoeconomics and Outcomes Research) to lead a workshop during the organisation’s international five-day conference in New Orleans.  The workshop will take place on Tuesday, May 21, 2013 at 17:00 CDT, and will focus on current global pricing and market access policies, and how they do and do not accommodate the unique nature of orphan disease designated drugs.

The session will be led by Ms. Monica Martin de Bustamante, Managing Director of CBPartners.  She will introduce the major issues, and Dr. Rachel Beckerman, Principal of Value Demonstration at CBPartners, will lead a review of the global health technology assessment (HTA) landscape, and the specific bylaws in place for orphan and ultra-orphan diseases.  Dr. Corinna Sorenson, Research Fellow of Health Policy at the London School of Economics will provide rationale for orphan disease access policies, with a particular focus on major European markets.  Ms. Meghan Gallagher, Director of Evidence Translation at Sanofi, will provide the drug developer’s perspective on orphan disease drug access.  Finally, Mr. Cyrus A. Chowdhury, CEO and Managing Director of CBPartners will provide additional global perspective on orphan disease drug brands and lessons learned in established and emerging markets.

“During the past decade, the number of therapies with first-indications for orphan and ultra-orphan diseases has steadily increased, however policy on access and value assessment of these unique therapies has yet to evolve,” explains Ms. Martin de Bustamante.  “It has gradually become apparent that HTA agencies are not going to make it easy for these products to achieve access.”

“At very least,” Mr. Chowdhury adds, “health economic models are being requested, and in some cases, their outputs are being used as part of a pricing and reimbursement evaluation process designed for therapies with substantially larger patient populations and very different disease dynamics.”

Manufacturers of these agents have lobbied for policy-makers to adapt their evaluation process to meet the specifications of orphan diseases. “Many companies have worked to educate policy-makers, and change is gradual, but eventual,” states Ms. Gallagher.

The discussion will be facilitated by orphan disease experts.  For a copy of the materials used during this workshop, please visit www.cbpartners.com or email info@cbpartners.com following the workshop.

About CBPartners
CBPartners is a leading global strategy consulting firm focusing on healthcare issues for a variety of clients, including biopharmaceutical / pharmaceutical companies, medical device companies and government health authorities. Headquartered in New York City, CBPartners maintains a continuous throughput of local market intelligence updates from advisors throughout over 70 countries. CBPartners provides expertise through five practice areas including Pricing and Market Access, Value Demonstration, Portfolio Optimisation, Commercial Planning, and Government Policy Advisory.

CBPartners Leads Full-Day Conference on Biosimilar Development and Commercialisation at the 2013 IBC Biosimilars Conference

Leading a panel of speakers that included global regulators, biosimilar manufacturers, and contract research organisations, CBPartners presented strategic insights and experiences from various biosimilar launches, as well as how originator brands plan to defend their leadership positions

New York City, February 28, 2013 – CBPartners, one of the world’s leading authorities on the development of pricing and market access strategy within the biosimilars space, led a full day biosimilars conference on February 27, 2013 in Los Angeles. The conference, organised by IBC, was chaired by Mr. Cyrus A. Chowdhury, Chief Executive Officer of CBPartners.

The day began with keynote speakers from the US Food and Drug Administration (FDA), Celltrion, and Boehringer Ingelheim. Dr. Jeffrey C. Baker, Deputy Director in the Office of Biotechnology Products at the FDA’s CDER provided an update on emerging issues related to the regulation of bioproducts. The opening address was delivered by Mr. Chowdhury, who led an hour-long session on strategies and tactics for commercial differentiation of biosimilars and originator biologic brands. The issues are of particular importance due to the limited opportunities that biosimilar manufacturers have to differentiate their products from originators without calling clinical effectiveness and safety into question.

“The entire premise of the biosimilar opportunity and value proposition to global healthcare authorities hinges upon providing similar healthcare outcomes to the originator product’s outcomes, while still providing an opportunity to reduce overall expenditure on biopharmaceuticals. Most biosimilar manufacturers are now learning that discounted pricing is only part of the value proposition – and may not always be sufficient to entice healthcare decision-makers to switch procurement to biosimilar options,” explains Mr. Chowdhury.

“Value can come in many forms,” continued Mr. Chowdhury. “In particular, experience with the original manufacturer, physician experience and comfort, device simplicity, disease management, and other value-add programmes are quite often the reason that many healthcare authorities have yet to make an aggressive switch to exclusively sourcing biosimilar options. Manufacturers need to soberly evaluate the magnitude of these value components to ensure an effective approach to managing the biosimilar phenomenon.”

Distribution of the presentation is currently limited to clients of CBPartners. For more information, please visit www.cbpartners.com.

About CBPartners
CBPartners is a leading global strategy consulting firm focusing on healthcare issues for a variety of clients, including biopharmaceutical companies, medical device companies and government health authorities. Headquartered in New York City, CBPartners maintains a continuous throughput of local market intelligence updates from advisors throughout 73 markets. CBPartners provides expertise through five practice areas including Pricing and Market Access, Value Demonstration, Portfolio Optimisation, Commercial Planning, and Government Policy Advisory.

To find out more, please contact Cyrus Chowdhury, Managing Director of the New York City office at cyrus.chowdhury@cbpartners.com, visit www.cbpartners.com, or follow CBPartners on Twitter: www.twitter.com/CBPartners.

CBPartners Releases New Thought Piece on HTA in the Emerging Markets

Developed by Rachel Beckerman, PhD, Principal of Value Demonstration at CBPartners, and Shinkyu Park, Analyst at CBPartners, the thought piece aims to elucidate the status of HTA adoption and implementation in the emerging markets by focusing on case studies from Brazil, Taiwan, and Korea

New York City, January 24, 2013 – CBPartners, one of the world’s leading authorities on issues related to the demonstration of value in support of pricing and market access strategy within the biopharmaceutical industry, officially publishes the analysis this afternoon at 1500 EST / 2100 CET. The piece, entitled “Guardians of Opportunity: Emerging HTA in Brazil, South Korea, and Taiwan” was collaboratively developed by Dr. Beckerman, Principal in the Value Demonstration practice in the New York City office, and Shinkyu Park, Analyst in the New York City office.

HTA, or Health Technology Assessment, is an evidence-based policy intervention applied by payers of biopharmaceuticals and other healthcare interventions. It is believed that HTA can lead to optimised expenditure of healthcare resources – however the most effective methodology of HTA is still contested among healthcare policy authorities around the world. During the past 15 years, HTA has flourished in Western European countries like England, Sweden, Scotland, Germany, and France. HTA has also been established in Commonwealth countries like Canada and Australia.

Until recently, however, HTA was not fully or consistently implemented in the emerging economies – and many argue that it is still not effectively employed in these markets. “Most biopharmaceutical manufacturers believe that the emerging economies represent great opportunity due to the rapidly evolving ability and willingness to pay for the latest in healthcare innovation,” explains Dr. Beckerman. “The use of HTA as a tool to efficiently spend financial resources on healthcare innovations is just now reaching countries like Brazil, Korea, and Taiwan. Thus far, we have learned of several telling case studies which indicate the additional degree of difficulty experienced by biopharmaceutical innovators through these policies.”

Many claim that emerging markets are not ready for the complicated methods and ramifications of an HTA-based system for determining access to innovative medicines. “No payer of biopharmaceuticals – anywhere in the world – has determined the perfect solution for evaluating value-for-money,” states Cyrus A. Chowdhury, Chief Executive Officer of CBPartners. “With cost-effectiveness methods ranging broadly from cost-utility to cost-minimisation and non-monetised incremental benefit assessments, it is clear that there is no consensus solution that can be applied to each society. This diversity of methods carries significant risk to biopharmaceutical manufacturers attempting to develop a concise global evidence strategy – risk that significantly increases through the addition of HTA to the already complex emerging market environment.”

Distribution of the thought piece is currently limited to clients of CBPartners, however the piece will be more broadly available in 90 days. For more information, please visit www.cbpartners.com.

About CBPartners
CBPartners is a leading global strategy consulting firm focusing on healthcare issues for a variety of clients, including biopharmaceutical companies, medical device companies and government health authorities. Headquartered in New York City, CBPartners maintains a continuous throughput of local market intelligence updates from advisors throughout 73 markets. CBPartners provides expertise through five practice areas including Pricing and Market Access, Value Demonstration, Portfolio Optimisation, Commercial Planning, and Government Policy Advisory.

To find out more, please contact Rachel Beckerman, PhD, Principal of Value Demonstration in the New York City office at rachel.beckerman@cbpartners.com, visit www.cbpartners.com, or follow CBPartners on Twitter:www.twitter.com/CBPartners.

CBPartners Opens West Coast USA Regional Operations in San Francisco to Support Clients on Strategy Engagements

Location will serve as a regional hub for clients based on the West Coast in the United States

San Francisco, September 26, 2012 – CBPartners, one of the world’s leading authorities on strategic issues related to healthcare, announced today the launch of its West Coast regional operations in San Francisco, California.

Principals based in San Francisco provide expertise to clients across all five of CBPartners’ practices. “We are excited to establish a presence on the West Coast to better serve the needs of the vibrant scientific community in the Bay Area and Southern California,” states Dr. Kevin Wong, Principal of Commercial Planning and Portfolio Optimisation. “We know that patients, innovation, and solving many of our greatest medical unmet needs are the driving forces for our West Coast clients, and we are committed to offering world-class strategic consulting support that will help our clients achieve these lofty goals.”

Engagement teams working with clients on the West Coast are supported by CBPartners’ GHAB (Global Health Advisory Board), as well as consultants from global headquarters in New York City and European operations in Basel, Switzerland. Engagement teams will work from San Francisco, as well as well as in-person and on-site at client headquarters on the West Coast and with their local affiliates in all corners of the world.

“We have a long history of supporting clients in both Northern and Southern California. By placing consultants closer to our clients, we will be able to elevate our level of service to meet our clients’ growing demands,” explains Cyrus Chowdhury, Chief Executive Officer of CBPartners.

Dr. Kevin Wong, Principal of Commercial Planning and Portfolio Optimisation with CBPartners, will lead the development of the San Francisco Office. “We are excited to replicate the excellence that CBPartners has created in New York City and Basel. We will preserve the unique CBPartners culture and consistent over-delivery that defines us – all while opening new channels and accessibility for our clients in California.”

As CBPartners enhances its North American and European operations, plans for Asia-Pac expansion are continuing to develop. The firm’s leadership expects to continue the growth of these offices through 2014 and beyond.

About CBPartners
CBPartners is a leading global strategy consulting firm focusing on healthcare issues for a variety of clients, including biopharmaceutical companies, medical device companies and government health authorities. Headquartered in New York City, CBPartners maintains a continuous throughput of local market intelligence updates from advisors throughout 73 markets. CBPartners provides expertise through five practice areas including Pricing and Market Access, Value Demonstration, Portfolio Optimisation, Commercial Planning, and Government Policy Advisory.

To find out more, please contact Cyrus Chowdhury, Managing Director of the New York City office at cyrus.chowdhury@cbpartners.com, visitwww.cbpartners.com, or follow CBPartners on Twitter:www.twitter.com/CBPartners.

CBPartners names Kevin Wong, Ph.D. Principal of Commercial Planning and Portfolio Optimisation

Kevin Wong brings over 12 years of industry experience spanning all phases of product lifecycle for issues ranging from pipeline decision analytics to in-line marketing strategy

San Francisco, September 17, 2012 – CBPartners, one of the world’s leading authorities on strategic issues related to healthcare, is excited to welcome Kevin Wong, Ph.D., to lead the Commercial Planning and Portfolio Optimisation practices, and to head the West Coast Office.

With a strong foundation in biopharmaceutical analytics, strategy and commercialisation, Dr. Wong provides an excellent strategic resource for clients around the globe. Dr. Wong’s work with Genentech as a Senior Product Manager and Senior Market Planning Manager spanned strategy and market analysis, as well as pipeline, in-line, and brand launch strategy across specialty biopharmaceutical and general medicine products. Dr. Wong also brings extensive pricing and market access expertise from his time as an engagement manager with IMS Consulting Group.

“CBPartners brings an edge to strategic consulting support uncommonly experienced by pharmaceutical companies these days,” Dr. Wong explains. “Having been both a consultant and a client, I recognised the philosophical difference between CBPartners and many other service providers. I am thrilled to join the team and lead the expansion of services to commercial planning and portfolio optimisation.”

Cyrus Chowdhury, CBPartners Chief Executive Officer, states “Dr. Wong’s deep commercial and consulting expertise raises our capabilities to new levels. The depth of our commercial insights will be significantly amplified through Dr. Wong’s commercial dexterity.”

Dr. Wong leads CBPartners’ San Francisco office, and will split time between the West Coast and New York City.

About CBPartners
CBPartners is a leading global strategy consulting firm focusing on healthcare issues for a variety of clients, including biopharmaceutical companies, medical device companies and government health authorities. Headquartered in New York City, CBPartners maintains a continuous throughput of local market intelligence updates from advisors throughout 73 markets. CBPartners provides expertise through five practice areas including Pricing and Market Access, Value Demonstration, Portfolio Optimisation, Commercial Planning, and Government Policy Advisory.